Last reviewed · How we verify
Inj. Octreotide
Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors.
Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors. Used for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome.
At a glance
| Generic name | Inj. Octreotide |
|---|---|
| Also known as | Inj Octride |
| Sponsor | PVS Memorial Hospital |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the secretion of growth hormone, insulin, and other hormones, and reduces splanchnic blood flow. These effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.
Approved indications
- Acromegaly
- Variceal bleeding in portal hypertension
- Carcinoid syndrome
- VIPoma
- Gastrinoma
- Neuroendocrine tumors
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Hyperglycemia
- Cholelithiasis
- Injection site pain
Key clinical trials
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (PHASE2)
- Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inj. Octreotide CI brief — competitive landscape report
- Inj. Octreotide updates RSS · CI watch RSS
- PVS Memorial Hospital portfolio CI